NOVT NOVANTA INC

Nasdaq novanta.com


$ 102.31 $ -1.81 (-1.69 %)    

Friday, 07-Nov-2025 17:01:36 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 105.45
$ 106.29
$ 100.00 x 20
$ 109.87 x 200
$ 101.44 - $ 106.29
$ 98.76 - $ 183.85
3,885,212
na
3.77B
$ 1.54
$ 71.42
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-26-2025 10-Q
2 08-05-2025 06-27-2025 10-Q
3 05-06-2025 03-28-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 11-05-2024 09-27-2024 10-Q
6 08-06-2024 06-28-2024 10-Q
7 05-07-2024 03-29-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-07-2023 09-29-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 07-01-2022 10-Q
15 05-10-2022 04-01-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-09-2021 10-01-2021 10-Q
18 08-10-2021 07-02-2021 10-Q
19 05-11-2021 04-02-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-10-2020 10-02-2020 10-Q
22 08-06-2020 07-03-2020 10-Q
23 05-12-2020 04-03-2020 10-Q
24 02-26-2020 12-31-2019 10-K
25 11-05-2019 09-27-2019 10-Q
26 08-06-2019 06-28-2019 10-Q
27 05-07-2019 03-29-2019 10-Q
28 02-27-2019 12-31-2018 10-K
29 11-06-2018 09-28-2018 10-Q
30 08-08-2018 06-29-2018 10-Q
31 05-08-2018 03-30-2018 10-Q
32 02-28-2018 12-31-2017 10-K
33 11-01-2017 09-29-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-08-2017 03-31-2017 10-Q
36 03-06-2017 12-31-2016 10-K
37 11-02-2016 09-30-2016 10-Q
38 08-02-2016 07-01-2016 10-Q
39 05-06-2016 04-01-2016 10-Q
40 03-02-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 novanta-raises-533m-through-50-per-unit-public-equity-offering-to-strengthen-balance-sheet-and-fund-growth-plans

Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced t...

 novanta-commences-550m-offering-of-11m-tangible-equity-units-at-50unit

Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced t...

 novanta-narrows-fy2025-adj-eps-guidance-from-322-336-to-324-330-vs-326-est-narrows-fy2025-sales-guidance-from-970000m-985000m-to-975000m-979000m-vs-977747m-est

Novanta (NASDAQ:NOVT) narrows FY2025 Adj EPS guidance from $3.22-$3.36 to $3.24-$3.30 vs $3.26 analyst estimate. Narrows FY2025...

 novanta-sees-q4-adj-eps-087-093-vs-094-est-sees-sales-253000m-257000m-vs-255160m-est

Novanta (NASDAQ:NOVT) is looking for Q4 Adj EPS of $0.87-$0.93 vs $0.94 analyst estimate. sees sales of $253.000 million-$257.0...

 novanta-q3-adj-eps-087-beats-082-estimate-sales-247836m-beat-245950m-estimate

Novanta (NASDAQ:NOVT) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.82 by 6.49...

 novanta-board-authorizes-repurchase-of-up-to-addl-200m-of-outstanding-common-shares-adding-capacity-to-31m-remaining-from-2020-board-authorization-for-total-capacity-of-231m

Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment m...

 baird-maintains-neutral-on-novanta-lowers-price-target-to-133

Baird analyst Robert Mason maintains Novanta (NASDAQ:NOVT) with a Neutral and lowers the price target from $139 to $133.

 novanta-lowers-fy2025-adj-eps-guidance-from-335-355-to-322-336-vs-337-est-lowers-fy2025-sales-guidance-from-1000b-to-970000m-985000m-vs-983167m-est

Novanta (NASDAQ:NOVT) lowers FY2025 Adj EPS guidance from $3.35-$3.55 to $3.22-$3.36 vs $3.37 analyst estimate. Lowers FY2025 s...

 novanta-sees-q3-adj-eps-078-085-vs-093-est-sees-sales-244000m-247000m-vs-254563m-est

Novanta (NASDAQ:NOVT) is looking for Q3 Adj EPS of $0.78-$0.85 vs $0.93 analyst estimate. sees sales of $244.000 million-$247.0...

 novanta-q2-adj-eps-076-beats-073-estimate-sales-241049m-beat-237987m-estimate

Novanta (NASDAQ:NOVT) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.73 by 3.68...

 baird-maintains-neutral-on-novanta-lowers-price-target-to-160

Baird analyst Robert Mason maintains Novanta (NASDAQ:NOVT) with a Neutral and lowers the price target from $169 to $160.

Core News & Articles

The partnership aims to streamline the adoption of intelligent, RFID-enabled solutions for medical device OEMs by combining Ide...

 novanta-expects-fy25-revenue-of-1b-vs-104b-est-adj-eps-of-335-355-vs-379-est

For the full year 2025, the Company expects GAAP revenue of approximately $1.0 billion, representing revenue growth of approxim...

 novanta-expects-q1-revenue-of-232m-236m-vs-24489m-est-adj-eps-of-063-071-vs-078-est

For the full year 2025, the Company expects GAAP revenue of approximately $1.0 billion, representing revenue growth of approxim...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION